Michele Caraglia

ORCID: 0000-0003-2408-6091
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Colorectal Cancer Treatments and Studies
  • Bone health and treatments
  • MicroRNA in disease regulation
  • Cancer Immunotherapy and Biomarkers
  • Protein Degradation and Inhibitors
  • Multiple Myeloma Research and Treatments
  • RNA Interference and Gene Delivery
  • Radiopharmaceutical Chemistry and Applications
  • Histone Deacetylase Inhibitors Research
  • Cancer-related molecular mechanisms research
  • Lung Cancer Treatments and Mutations
  • Immunotherapy and Immune Responses
  • Peptidase Inhibition and Analysis
  • Cancer Genomics and Diagnostics
  • Prostate Cancer Treatment and Research
  • Autophagy in Disease and Therapy
  • Cancer Mechanisms and Therapy
  • Lung Cancer Research Studies
  • Cancer Treatment and Pharmacology
  • Hepatocellular Carcinoma Treatment and Prognosis
  • Nanoparticle-Based Drug Delivery
  • HER2/EGFR in Cancer Research
  • RNA modifications and cancer
  • PI3K/AKT/mTOR signaling in cancer
  • Brain Metastases and Treatment

University of Campania "Luigi Vanvitelli"
2016-2025

Biogem
2019-2025

Livestrong Foundation
2024

Istituti Clinici Scientifici Maugeri
2019

GTx (United States)
2019

University of Naples Federico II
2009-2018

Temple University
2012-2018

Sbarro Health Research Organization
2018

Universidade Federal do Amazonas
2018

University of Siena
2015-2017

The present study was designed to evaluate the effects of diet lifestyle on extending lifespan and reducing liver cancer risk. Young overweight men (n = 20), without metabolic syndrome, were placed in a 3-week residential program low-fat moderate aerobic exercise. In each subject, pre- postintervention fasting blood collected for evaluating levels serum lipids, oxidative stress markers. Using subject sera cardiomyocyte (H9C2) culture systems, we measured heat shock protein 27 90 expression,...

10.1155/2014/131024 article EN cc-by Oxidative Medicine and Cellular Longevity 2014-01-01

Deregulated expression of miRNAs has been shown in multiple myeloma (MM). A promising strategy to achieve a therapeutic effect by targeting the miRNA regulatory network is enforce that act as tumor suppressor genes, such miR-34a.Here, we investigated potential synthetic miR-34a against human MM cells vitro and vivo.Either transient mimics or lentivirus-based miR-34a-stable enforced triggered growth inhibition apoptosis vitro. Synthetic downregulated canonic targets BCL2, CDK6, NOTCH1 at both...

10.1158/1078-0432.ccr-12-1708 article EN Clinical Cancer Research 2012-10-04

Abstract Pentose phosphate pathway (PPP) is a major glucose metabolism pathway, which has fundamental role in cancer growth and metastasis. Even though PPP blockade been pointed out as very promising strategy against cancer, effective anti-PPP agents are not still available the clinical setting. Here we demonstrate that natural molecule polydatin inhibits glucose-6-phosphate dehydrogenase (G6PD), key enzyme of PPP. Polydatin blocks G6PD causing accumulation reactive oxygen species strong...

10.1038/s41419-018-0635-5 article EN cc-by Cell Death and Disease 2018-05-14

Gemcitabine (GEM, 2′,2′-difluorodeoxycytidine) is currently used in advanced pancreatic adenocarcinoma, with a response rate of < 20%. The purpose our work was to improve GEM activity by addition cannabinoids. Here, we show that induces both cannabinoid receptor-1 (CB1) and receptor-2 (CB2) receptors an NF-κB-dependent mechanism its association cannabinoids synergistically inhibits adenocarcinoma cell growth increases reactive oxygen species (ROS) induced single treatments. antiproliferative...

10.1038/cddis.2011.36 article EN cc-by Cell Death and Disease 2011-04-28

Abstract Skeletal homeostasis relies upon a fine tuning of osteoclast (OCL)‐mediated bone resorption and osteoblast (OBL)‐dependent formation. This balance is unsettled by multiple myeloma (MM) cells, which impair OBL function stimulate OCLs to generate lytic lesions. Emerging experimental evidence disclosing key regulatory role microRNAs (miRNAs) in the regulation suggesting miRNA network as potential novel target for treatment MM‐related disease (BD). Here, we report that miR‐29b...

10.1002/jcp.24306 article EN Journal of Cellular Physiology 2012-12-18

Sorafenib is an oral multikinase inhibitor that targets Raf kinase and receptor tyrosine kinases has led to a longer median overall survival (OS) time progression (TTP) in patients with advanced hepatocellular carcinoma (HCC). This study was conducted assess the link between antitumor efficacy of sorafenib its early cutaneous side effects HCC patients.All received 800 mg daily until or unacceptable toxicities. We retrospectively analyzed incidence rash hand-foot skin reactions (HFSR) during...

10.1634/theoncologist.2009-0143 article EN The Oncologist 2010-01-01

Purpose Approximately 30% to 40% patients with a superficial bladder cancer treated Bacille Calmette-Guerin (BCG) or epirubicin do not respond; of the initial responders, 35% have relapse within 5 years. We compare therapeutic efficacy and toxicity intravescical infusions gemcitabine (GEM) mitomycin (MMC) in recurrent cancer. Patients Methods history previously treated, Ta-T1, G1-G3 transitional cell carcinoma were enrolled study. The received 6-week course GEM 4-week MMC. In both arms, for...

10.1200/jco.2008.20.8199 article EN Journal of Clinical Oncology 2009-10-20

Abstract Purpose: On the basis of stimulating data on animals reporting that weekly regimens zoledronic acid (ZA) were effective in reducing skeletal tumor burden, we designed a study humans to investigate potential antiangiogenic role low-dose therapy with ZA patients malignancies. Experimental Design: Twenty-six consecutive advanced solid cancer and bone metastases received 1 mg every week for four times (days 1, 7, 14, 21) followed by 4 standard 28-day schedule repeated thrice 28, 56,...

10.1158/1078-0432.ccr-07-0551 article EN Clinical Cancer Research 2007-08-01

MicroRNAs (miRNAs) with tumor-suppressor potential might have therapeutic applications in multiple myeloma (MM) through the modulation of still undiscovered molecular pathways. Here, we investigated effects enforced expression miR-29b on apoptotic occurrence MM and highlighted its role context a new transcriptional loop that is finely tuned by proteasome inhibitor bortezomib. In details, vitro growth inhibition apoptosis cells was induced either transient synthetic or stable...

10.1038/cddis.2012.175 article EN cc-by Cell Death and Disease 2012-11-29

Aberrant DNA methylation plays a relevant role in multiple myeloma (MM) pathogenesis. MicroRNAs (miRNAs) are class of small non-coding RNAs that recently emerged as master regulator gene expression by targeting protein-coding mRNAs. However, miRNAs involvement the regulation epigenetic machinery and their potential use therapeutics MM remain to be investigated. Here, we provide evidence de novo methyltransferases (DNMTs) is deregulated cells. Moreover, show miR-29b targets DNMT3A DNMT3B...

10.18632/oncotarget.675 article EN cc-by Oncotarget 2012-10-21

Abstract Potentiation of epidermal growth factor receptor (EGFR) inhibitors is required in squamous cell carcinoma head and neck (SCCHN) to improve their therapeutic index. We demonstrated that the histone deacetylase inhibitor vorinostat combination with EGFR tyrosine kinase gefitinib induced synergistic inhibition proliferation, migration, invasion as well induction apoptosis SCCHN cells, including cells resistant gefitinib. provided evidence suggesting differential modulation ErbB...

10.1002/jcp.22574 article EN Journal of Cellular Physiology 2010-12-09

Hepatocellular carcinoma (HCC) is the third cause of cancer-related deaths worldwide. Sorafenib only approved drug for patients with advanced HCC but has shown limited activity. microRNAs (miRs) have been involved in several neoplasms including suggesting their use or targeting as good tools treatment. The purpose this study was to identify novel approaches sensitize cells sorafenib through miRs. miR-423-5p validated positive regulator autophagy cell lines by transient transfection miR and...

10.1038/mtna.2015.8 article EN cc-by-nc-nd Molecular Therapy — Nucleic Acids 2015-01-01

Inhibition of distinct ubiquitin E3 ligases might represent a powerful therapeutic tool. ITCH is HECT domain-containing ligase that promotes the ubiquitylation and degradation several proteins, including p73, p63, c-Jun, JunB, Notch c-FLIP, thus affecting cell fate. Accordingly, depletion potentiates effect chemotherapeutic drugs, revealing as potential pharmacological target in cancer therapy. Using high throughput screening auto-ubiquitylation, we identified putative inhibitors, one which...

10.1038/cddis.2014.113 article EN cc-by Cell Death and Disease 2014-05-01

Abstract Background Cardiotoxicity is a major complication of anticancer drugs, including anthracyclines and 5-fluorouracil(5-FU) it can have detrimental effects both in patients workers involved the preparation chemotherapy. Methods Specifically, we assessed increasing concentrations 5-FU doxorubicin (DOXO) on proliferation H9c2 rat cardiocytes HT-29 human colon adenocarcinoma cells by MTT assay. Cells were treated for 24, 48 72 h with different two drugs alone or combination 10 -4 M...

10.1186/1756-9966-31-60 article EN cc-by Journal of Experimental & Clinical Cancer Research 2012-07-19
Coming Soon ...